Indivior Pharmaceuticals, Inc.

425 supplemental

425 supplemental

EFFECT effective

424B3 priced

The current filing includes Indivior's standalone financial projections for 2026-2040, prepared without considering merger-related impacts like cost synergies or operational changes. These projections are non-GAAP, unaudited, and accompanied by significant cautionary notes about their reliability. The document also references adjusted financial measures and highlights risks related to assumptions, market conditions, and the merger's outcome. Supernus's standalone projections are included but adjusted by Indivior management, with additional synergy estimates for the combined company.

S-4/A amended

S-4 filed

425 supplemental

425 supplemental

425 supplemental

425 supplemental

425 supplemental

20-F supplemental

CERT inactive

DRS/A amended

Indivior Pharmaceuticals reported 2022 financial results showing $901 million in net revenues, a 14% increase from 2021, driven by growth in SUBLOCADE (45% of revenue vs. 31% in 2021) and PERSERIS. However, the company recorded an operating loss of $85 million in 2022 compared to $213 million operating profit in 2021, primarily due to a $290 million litigation provision. Net income fell to a $53 million loss from $205 million profit, with tax expenses rising amid UK tax rate changes and reduced innovation incentives. International revenue declined 10% due to foreign exchange impacts and competitive pressures, while U.S. revenue grew 21%.

DRS/A amended

Indivior Pharmaceuticals reported a significant decline in operating profit in 2022, driven by increased litigation provisions and higher operating expenses. Net revenues grew 14% to $901 million, fueled by strong performance in SUBLOCADE and PERSERIS. However, the company faced challenges in international markets due to currency fluctuations and competitive pressures. The operating loss of $85 million in 2022 contrasts sharply with the $213 million profit in 2021, primarily due to exceptional litigation costs. Adjusted net income remained positive at $169 million, reflecting underlying revenue growth despite rising expenses.

DRS/A amended

Indivior Pharmaceuticals reported strong revenue growth in Q3 2022 and YTD 2022, driven by increased sales of SUBLOCADE and PERSERIS. Net revenues rose 24% QoQ to $232M and 16% YoY to $659M, with SUBLOCADE contributing 44% of YTD 2022 revenues. U.S. revenues grew 25% YoY to $533M, while rest-of-world revenues declined 10% YoY to $126M due to currency translation and competitive pressures. Gross margin decreased slightly to 83% in Q3 2022, and operating profit reached $173M for YTD 2022. The company highlighted ongoing challenges in international markets and reliance on key products.

DRS/A amended

Indivior Pharmaceuticals, Inc. reported strong financial performance in 2022, driven by significant growth in net revenues from SUBLOCADE, PERSERIS, and other buprenorphine-based products. Net revenues increased by 16% year-to-date (YTD) 2022 to $659 million, with SUBLOCADE contributing 44% of total revenues. The U.S. market remained the primary revenue driver, while international operations faced challenges from foreign currency fluctuations and competitive pressures. Adjusted operating profit rose to $172 million YTD 2022, reflecting revenue growth and strategic investments, though gross margins declined slightly due to lower-margin government channel sales and increased manufacturing costs. Tax rates and exceptional items also impacted financial results, with adjusted metrics providing a clearer view of ongoing operations.

DRS filed

Indivior Pharmaceuticals reported strong revenue growth in Q3 2022 and YTD 2022, driven by increased sales of SUBLOCADE, PERSERIS, and other buprenorphine-based products. U.S. net revenue grew 25% year-to-date and 32% sequentially, while international revenue declined 10% year-to-date due to currency effects and competitive pressures. Adjusted operating profit increased 47% sequentially and 3% year-to-date, despite rising R&D and SG&A expenses. The company highlighted resilience in SUBOXONE Film market share and ongoing challenges with generic competition in the BMAT market.

EFFECT effective